207 related articles for article (PubMed ID: 24097108)
1. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Vicier C; Dieci MV; Andre F
Curr Opin Oncol; 2013 Nov; 25(6):587-93. PubMed ID: 24097108
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
3. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Ciruelos E; Cortes-Funes H; Ghanem I; Manso L; Arteaga C
Anticancer Drugs; 2013 Sep; 24(8):769-80. PubMed ID: 23838677
[TBL] [Abstract][Full Text] [Related]
4. [BOLERO -- another remarkable step in treatment of breast cancer].
Rubovszky G; Láng I
Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
[TBL] [Abstract][Full Text] [Related]
5. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
Wilks ST
Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
[TBL] [Abstract][Full Text] [Related]
6. Overcoming resistance to rapalogs in gliomas by combinatory therapies.
Grzmil M; Hemmings BA
Biochim Biophys Acta; 2013 Jul; 1834(7):1371-80. PubMed ID: 23395884
[TBL] [Abstract][Full Text] [Related]
7. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
8. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors in the treatment of breast cancer.
Vinayak S; Carlson RW
Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041
[TBL] [Abstract][Full Text] [Related]
10. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
11. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
Barnett CM
Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Gombos A; Barthélémy P; Awada A
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):823-34. PubMed ID: 25659402
[TBL] [Abstract][Full Text] [Related]
13. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
15. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors in advanced breast cancer: ready for prime time?
Martin LA; André F; Campone M; Bachelot T; Jerusalem G
Cancer Treat Rev; 2013 Nov; 39(7):742-52. PubMed ID: 23557794
[TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
18. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.
Keck S; Glencer AC; Rugo HS
Future Oncol; 2012 Nov; 8(11):1383-96. PubMed ID: 23148612
[TBL] [Abstract][Full Text] [Related]
19. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
Austreid E; Lonning PE; Eikesdal HP
Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
[TBL] [Abstract][Full Text] [Related]
20. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
Malaguti P; Vari S; Cognetti F; Fabi A
Anticancer Res; 2013 Jan; 33(1):21-8. PubMed ID: 23267124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]